WARNING: DIMINISHED ANTIPLATELET EFFECT IN PATIENTS WITH TWO LOSS-OF-FUNCTION ALLELES OF THE CYP2C19 GENE WARNING: DIMINISHED ANTIPLATELET EFFECT IN PATIENTS WITH TWO LOSS-OF-FUNCTION ALLELES OF THE CYP2C19 GENE See full prescribing information for complete boxed warning. Effectiveness of Plavix depends on conversion to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19.
(5.1, 12.3) Tests are available to identify patients who are CYP2C19 poor metabolizers. (12.5) Consider use of another platelet P2Y 12 inhibitor in patients identified as CYP2C19 poor metabolizers. (5.1) The effectiveness of Plavix results from its antiplatelet activity, which is dependent on its conversion to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19 [see Warnings and Precautions (5.1), Clinical Pharmacology (12.3)].
Plavix at recommended doses forms less of the active metabolite and so has a reduced effect on platelet activity in patients who are homozygous for nonfunctional alleles of the CYP2C19 gene, (termed "CYP2C19 poor metabolizers"). Tests are available to identify patients who are CYP2C19 poor metabolizers [see Clinical Pharmacology (12.5)].
Consider use of another platelet P2Y 12 inhibitor in patients identified as CYP2C19 poor metabolizers.
Use: Labeled indications
- Acute coronary syndrome – For patients with non–ST-segment elevation ACS (unstable angina [UA]/non–ST-elevation myocardial infarction [NSTEMI]), Plavix has been shown to reduce the rate of myocardial infarction (MI) and…
- – For patients with ST-elevation myocardial infarction (STEMI), Plavix has been shown to reduce the rate of MI and stroke.
- Recent MI, recent stroke, or established peripheral arterial disease.
Full indications and usage US FDA label
1 INDICATIONS AND USAGE Plavix is a P2Y 12 platelet inhibitor indicated for: Acute coronary syndrome – For patients with non–ST-segment elevation ACS (unstable angina [UA]/non–ST-elevation myocardial infarction [NSTEMI]), Plavix has been shown to reduce the rate of myocardial infarction (MI) and stroke. (1.1) – For patients with ST-elevation myocardial infarction (STEMI), Plavix has been shown to reduce the rate of MI and stroke.
(1.1) Recent MI, recent stroke, or established peripheral arterial disease. Plavix has been shown to reduce the rate of MI and stroke. (1.2) 1.1 Acute Coronary Syndrome (ACS) Plavix is indicated to reduce the rate of myocardial infarction (MI) and stroke in patients with non–ST-segment elevation ACS (unstable angina [UA]/non–ST-elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those who are to be managed with coronary revascularization.
Plavix should be administered in conjunction with aspirin. Plavix is indicated to reduce the rate of myocardial infarction and stroke in patients with acute ST-elevation myocardial infarction (STEMI) who are to be managed medically. Plavix should be administered in conjunction with aspirin. 1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease In patients with established peripheral arterial disease or with a history of recent myocardial infarction (MI) or recent stroke Plavix is indicated to reduce the rate of MI and stroke.
Contraindications
4 CONTRAINDICATIONS Active pathological bleeding, such as peptic ulcer or intracranial hemorrhage (4.1) Hypersensitivity to clopidogrel or any component of the product (4.2) 4.1 Active Bleeding Plavix is contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage. 4.2 Hypersensitivity Plavix is contraindicated in patients with hypersensitivity (e.g., anaphylaxis) to clopidogrel or any component of the product [see Adverse Reactions (6.2)].
US FDA labelDosing: Adult
- Acute coronary syndrome (2.1)
- – Initiate Plavix with a single 300 mg oral loading dose and then continue at 75 mg once daily. – Initiating Plavix without a loading dose will delay establishment of an antiplatelet effect by several days. Recent MI, recent stroke, or established peripheral arterial disease: 75 mg once daily orally without a loading dose. (2.2)
2.1 Acute Coronary Syndrome
2.1 Acute Coronary Syndrome In patients who need an antiplatelet effect within hours, initiate Plavix with a single 300 mg oral loading dose and then continue at 75 mg once daily. Initiating Plavix without a loading dose will delay establishment of an antiplatelet effect by several days [see Clinical Pharmacology (12.3) and Clinical Studies (14.1)].
2.2 Recent MI
2.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease 75 mg once daily orally without a loading dose [see Clinical Pharmacology (12.3) and Clinical Studies (14.2)].
Dosing: Altered kidney function
8.6 Renal Impairment Experience is limited in patients with severe and moderate renal impairment [see Clinical Pharmacology (12.2)].
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Hepatic impairment
8.7 Hepatic Impairment No dosage adjustment is necessary in patients with hepatic impairment [see Clinical Pharmacology (12.2)].
US FDA labelDosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use Safety and effectiveness in pediatric populations have not been established. A randomized, placebo-controlled trial (CLARINET) did not demonstrate a clinical benefit of clopidogrel in neonates and infants with cyanotic congenital heart disease palliated with a systemic-to-pulmonary arterial shunt. Possible factors contributing to this outcome were the dose of clopidogrel, the concomitant administration of aspirin, and the late initiation of therapy following shunt palliation.
It cannot be ruled out that a trial with a different design would demonstrate a clinical benefit in this patient population.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Of the total number of subjects in the CAPRIE and CURE controlled clinical studies, approximately 50% of patients treated with Plavix were 65 years of age and older, and 15% were 75 years and older. In COMMIT, approximately 58% of the patients treated with Plavix were 60 years and older, 26% of whom were 70 years and older.
The observed risk of bleeding events with Plavix plus aspirin versus placebo plus aspirin by age category is provided in Table 1 and Table 2 for the CURE and COMMIT trials, respectively [see Adverse Reactions (6.1)]. No dosage adjustment is necessary in elderly patients.
Dosage forms
Philippines
- Film-coated tablet: 75 mg, 300 mg
- Tablet: 75 mg
- Film – coated tablet: 75 mg
- Film–coated tablet: 75 mg
- Syrup: 6 mg/mL
Registered products in the Philippines
196 products registered with the Food and Drug Administration (FDA) Philippines list Clopidogrel as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.
Also registered under: Clopidgrel (as bisulfate) (1 product) · Clopidrogel (as bisulfate) (1 product). Products registered under these spellings are included in the table and marked.
All registered products196
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
75 mg Film-Coated TabletAlu/PVC blister pack x 15's (Box of 30's) | Rx | Akriti Pharmaceuticals Pvt. Ltd.India | Aglobal Care, Inc.Trader: N/A | DRP-16737 | Jul 1, 2030 | ||
AngiogrelClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 14’s) | Rx | Sandoz Private LimitedIndia | TGP Pharma Inc.Importer: Sandoz Philippines Corporation | DRP-2123-01 | Oct 14, 2029 | |
Angiostar 75Clopidogrel | 75mg Film-Coated TabletALU/ALU Blister pack 3 X 10's in a box | Rx | Celogen Generics Private Ltd.India | Pharmastar International Trading Corporation | DRP-11769 | Apr 27, 2027 | |
AnplatClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's, 50's and 100's) | Rx | Zim Laboratories LimitedIndia | Better Option Pharmaceuticals, Inc.Importer: Orange Biotec Inc.Trader: Amegh Pharma Pvt. Ltd. | DRP-3250 | Sep 20, 2031 | |
AnticlopClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Zim Laboratories LimitedIndia | Teramedix Pharma Trading Inc. | DRP-16500 | Mar 14, 2027 | |
AnticlopClopidogrel (as bisulfate) | 75mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Zim Laboratories LimitedIndia | Teramedix Pharma Trading Inc. | DR-XY47816 | Mar 14, 2027 | |
ArnopletClopidogrel (as Bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Saga LaboratoriesIndia | Hexagon Pharmaceuticals | DR-XY40696 | Mar 30, 2027 | |
AtegraClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Bafna Pharmaceuticals LimitedIndia | Novocore Pharma Inc.Importer: Medethix, Inc. | DRP-16366-01 | Feb 20, 2030 | |
AtegraClopidogrel (as Bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Mepro Pharmaceuticals Private LimitedIndia | Oxpharma Inc.Importer: Medethix Inc. | DRP-8514-06 | Nov 22, 2027 | |
CardigrelClopidogrel (as Bisulfate) | 75 mg Film-Coated TabletAlu-Alu Blister Pack Of 10'S (Box Of 30'S. Box Of 100'S) | Rx | Windlas Biotech Limited (Plant 2)India | Synergia Health Care & Life Sciences, Inc. | DRP-19056 | Oct 21, 2031 | |
CardiplatClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s; Box of 100’s) | Rx | Zim Laboratories LimitedIndia | GA2 Pharmaceutical Inc.Importer: Medinova Pharmaceutical Inc. | DRP-9166-08 | Oct 30, 2031 | |
CardogrelClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 7's Box of 14's | Rx | Sandoz Private LimitedIndia | Sandoz Philippines Corporation | DRP-2123 | Oct 14, 2029 | |
CassagrelClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister pack x 10's (Box of 100's) | Rx | Zim Laboratories LimitedIndia | Cassandras Care Pharmaceutical DistributorImporter: Medinova Pharmaceutical Inc. | DRP-9166-02 | Oct 30, 2031 | |
CastegrelClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | Castellano DrugImporter: Ambica International Corporation | DRP-2672-11 | Jan 4, 2029 | |
Cigrel-75Clopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack 5 x 10's (Box of 50's); Alu/Alu Blister Pack 10 x 10's (Box of 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | Medcare PharmaceuticalsImporter: Ambica International Corporation | DRP-5426 | Aug 8, 2029 | |
ClapidzClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | D&G PharmaImporter: Ambica International Corporation | DRP-2672-09 | Jan 4, 2029 | |
ClassClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-2672 | Jan 4, 2029 | |
ClodiClopidogrel (as Bisulfate) | 75mg Film-Coated TabletAlu/Alu Blister pack x 10's Box of 30's and 100's | Rx | MEPRO PHARMACEUTICALS Private LimitedIndia | AFFOMEDZ INC.Importer: MEDETHIX INC. | DRP-8514-02 | Nov 22, 2027 | |
CloduzClopidogrel (As bisuIfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's, 50's, & 100's) | Rx | Magbro Healthcare Pvt. Ltd.India | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-10878-04 | Dec 10, 2026 | |
CloedClopidogrel | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Centurion Laboratories Pvt. Ltd.India | Harlem SalesImporter: Philgen Pharmaceuticals Inc. | DRP-11057-08 | Jan 20, 2027 | |
ClogeovixClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's, 30's and 100's) | Rx | Medico Remedies LimitedIndia | MedEthix, Inc.Importer: I.E. Medica, Inc. | DRP-4539 | Jul 23, 2028 | |
ClogrelClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Surien Pharmaceuticals (P) Ltd.India | Brel Pharmaceutical Inc. | DR-XY41804 | Mar 14, 2028 | |
ClogretabClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation | DRP-2672-13 | Jan 4, 2029 | |
ClogrixClopidogrel (as bisuIfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's, 50's & 100's) | Rx | Magbro Healthcare Pvt. Ltd.India | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-10878-07 | Dec 10, 2026 | |
ClohealClopidogrel | 75 mg Film–Coated TabletAlu/Alu Blister Pack x 10’s (Box of 50’s and 100’s) | Rx | Stallion Laboratories Pvt. Ltd.India | Suhitas Pharmaceuticals Inc.Trader: Mac Heal Laboratories Ltd. | DRP-1791 | Aug 17, 2029 | |
ClomepClopidogrel (as bisulfate) | 75 mg Film - Coated TabletAlu/Alu Blister pack x 10's Box of 30's and 100's | Rx | MEPRO Pharmaceutical Private LimitedIndia | MEEDPHARMA MEDICAL SUPPLIES & EQUIPMENT DISTRIBUTORImporter: MEDETHIX INC. | DRP-8514-04 | Nov 22, 2027 | |
ClopateClopidogrel | 75 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 10's & Box of 30's) | Rx | Unicure Remedies Pvt. LtdIndia | ECE Pharmaceuticals, Inc.Importer: AAA Pharma, Inc. | DR-XY41747 | Feb 25, 2028 | |
ClopegenClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Zim Laboratories LimitedIndia | Reta DrugImporter: Medinova Pharmaceutical Inc. | DRP-9166-01 | Oct 30, 2031 | |
Clopend-75Clopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd. | DRP-4698 | Sep 13, 2028 | |
ClophilClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 100's | Rx | Stallion Laboratories Pvt. Ltd.India | Phil Asia Pharma IncImporter: Ambica International Corporation | DRP-2672-05 | Jan 4, 2029 | |
Clopi-HealthClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 100's | Rx | Sapphire Lifesciences Pvt. Ltd.India | HEALTHWINDS MEDICAL TRADING CORPImporter: Nelpa Lifesciences, Inc. | DRP-7384- | Oct 4, 2027 | |
ClopicardClopidogrel (as bisulfate) | 75mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Zim Laboratories LimitedIndia | Life And Health Source Pharmaceutical Distribution Co.Importer: Medinova Pharmaceutical Inc. | DRP-9166-06 | Feb 7, 2032 | |
ClopiclotClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/PVC Blister Pack of 10's (Box of 100's) | Rx | J. Duncan Healthcare Pvt. LtdIndia | Neos-King Pharma Inc.Importer: Grovic Pharma Inc. | DRP-12391-03 | Jul 13, 2027 | |
ClopidaClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | XL Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-1885 | Sep 8, 2029 | |
ClopidamondClopidogrel (as Bisulfate) | 75 mg TabletAluminum Foil Strip x 4's (Box of 100's) | Rx | Diamond Laboratories Inc.Philippines | Tobie Pharma, Inc. | DRP-7604-01 | Apr 11, 2029 | |
ClopidcuraClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 10's, 30's, 50's and 100's) | Rx | BDA Healthcare Pvt. Ltd.India | RVM Pharma & Medical Supplies DistributionImporter: Orange Biotec, Inc. | DRP-15765-02 | Sep 12, 2029 | |
Clopido-MClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | Zim Laboratories LimitedIndia | Rilem Pharma Corp.Importer: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-4528 | Nov 6, 2031 | |
ClopidogenClopidogrel | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Zim Laboratories, LimitedIndia | Quad-Gen PharmaceuticalsImporter: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-4528-03 | Dec 6, 2026 | |
ClopidoMedClopidogrel (as bisulfate) | 75mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Rhydburg Pharmaceuticals Limited.India | Dreamax IncorporatedTrader: Oak and Zen | DRP-14839 | Jan 22, 2029 | |
Clopidowel-75Clopidogrel (as bisulfate) | 75 mg Film-Coated TabletClear PVC/Alu Blister Pack x 10’s (Box of 100’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India | Guimhealth Pharmaceutical Distributor & DrugstoreImporter: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-3126 | Jul 14, 2029 | |
ClopidraClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Strip Foil x 4's (Box of 12's and 100's); Alu/Alu Strip Foil x 4's (Box of 8's as Physician's Sample); Alu/Alu Strip Foil x 2's (Box of 2's as Physician's Sample) | Rx | Interphil Laboratories, Inc.Philippines | — | DRP-3793 | Jun 13, 2028 | |
ClopidrelClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/White PVC Blister Pack x 10's (Box of 50's and 100's) | Rx | Medisure Laboratories Pakistan (Pvt.) LimitedPakistan | Accesspoint International Trading Inc. | DRP-6042 | Mar 13, 2030 | |
ClopierraClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Magbro Healthcare Pvt. Ltd.India | Sierra Pharmaceutical CorporationImporter: Pharmakon Biotec Inc. | DRP-10878-10 | Dec 10, 2026 | |
ClopifarClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's); Alu/Clear PVC Blister Pack x 10's (Box of 30's) | Rx | Bal Pharma LimitedIndia | Conjug8 Corp.Importer: Pharmakon Biotec Inc. | DRP-4875 | Oct 29, 2028 | |
ClopifirstClopidogrel | 75 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's) | Rx | J.M. Tolmann Laboratories Inc.Philippines | Firstmed Theraconcept Inc. | DRP-2470-10 | Feb 2, 2030 | |
ClopilarClopidogrel | 75 mg Film – Coated TabletAlu/Alu Blister Pack x 10’s (Box of 50’s and 100’s) | Rx | Stallion Laboratories Pvt. Ltd.India | Better Option Pharmaceuticals, Inc.Importer: Suhitas Pharmaceuticals Inc.Trader: Mac Heal Laboratories Ltd. | DRP-1791-03 | Aug 17, 2029 | |
ClopimedClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Medchem International LimitedIndia | Pharma-Surrey International, Inc. | DR-XY39280 | Apr 7, 2031 | |
ClopinavClopidogrel (as bisulfite) | 75 mg Film-Coated TabletAlu/White PVC Blister Pack x 10's (Box of 100's) | Rx | Medisure Laboratories Pakistan (Pvt.) LimitedPakistan | Rexmed Pharmaceutical SalesImporter: Accesspoint International Trading Inc. | DRP-6042-02 | Mar 13, 2030 | |
ClopinovaClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | Zim Laboratories LimitedIndia | Medinova Pharmaceutical Inc. | DRP-9166 | Sep 21, 2030 | |
ClopinovaClopidogrel (as bisulfate) | 75mg Film Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's and Box of 100's) | Rx | S Kant Healthcare Ltd.India | Medinova Pharmaceutical Inc. | DRP-18339 | Jun 16, 2031 | |
ClopiskyClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s; Box of 100’s) | Rx | Zim Laboratories LimitedIndia | Skymed Pharma DistributorImporter: Medinova Pharmaceutical Inc. | DRP-9166-09 | Oct 14, 2031 | |
CLOPISTANCLOPIDOGREL | 75 MG FILM-COATED TABLETALU / ALU BLISTER PACK X 10'S (Box of 30's) | Rx | J.M. TOLMANN LABORATORIES INC.Philippines | GOLD LIFE DISTRIBUTION PHILS. INC. | DRP-2470-13 | Feb 2, 2030 | |
ClopisureClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack of x 10's (Box of 100's) | Rx | Magbro Healthcare Pvt. Ltd.India | Rule Med Pharma Corp.Importer: Pharmakon Biotec Inc. | DRP-10878-11 | Dec 10, 2026 | |
ClopisureClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu / Alu Blister Pack x 10's (Box of 100's) | Rx | Zim Laboratories LimitedIndia | Rule Med Pharma Corp.Importer: Teramedix Pharma Trading Inc. | DRP-16500-01 | Mar 14, 2027 | |
ClopivateClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's and Box of 100's) | Rx | S Kant Healthcare Ltd.India | K Pharma Medical Corp.Importer: Medinova Pharmaceutical Inc. | DRP-18339-01 | Jun 16, 2031 | |
ClopivateClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | Zim Laboratories LimitedIndia | K Pharma Medical Corp.Importer: Medinova Pharmaceutical Inc. | DRP-9166-12 | Sep 21, 2030 | |
ClopivazClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Innogen Pharmaceuticals, Inc. | DRP-15262 | Jul 26, 2031 | |
Clopiwin-75Clopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | Mediwin PharmaceuticalsIndia | Ambica International Corporation | DRP-6560 | Oct 10, 2030 | |
ClopixClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Medhaus Pharma, Incorporated | DR-XY37363 | Jan 19, 2030 | |
ClopixelClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's and Box of 100's) | Rx | S Kant Healthcare Ltd.India | Medcare PharmaceuticalsImporter: Medinova Pharmaceutical Inc. | DRP-18339-02 | Jun 16, 2031 | |
ClopixelClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | Zim Laboratories LimitedIndia | Medcare PharmaceuticalsImporter: Medinova Pharmaceutical Inc. | DRP-9166-13 | Sep 21, 2030 | |
CloplatClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/ Alu Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | OEP Philippines, Inc.Importer: Ambica International Corporation | DRP-2672-17 | Jan 4, 2029 | |
ClopsilClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | XL Laboratories Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-1885-01 | Sep 8, 2029 | |
CloredClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | Rx | Sapphire Lifesciences Pvt. Ltd.India | 777 Red Pharma Inc.Importer: Nelpa Lifesciences, Inc. | DRP-7384-02 | Oct 4, 2027 | |
ClorelClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu / Alu Blister Pack x 10’s (Box of 100’s) | Rx | Hizon Laboratories, Inc.Philippines | Crisdy-Na Drug Corporation | DRP-6838-03 | Nov 17, 2029 | |
ClotfixmedClopidogrel | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Zim Laboratories, LimitedIndia | TGP Pharma Inc.Importer: Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-4528-02 | Dec 3, 2026 | |
ClotfreClopidogrel | 75 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's and 100's) | Rx | Raptakos, Brett & Co., LtdIndia | Raptakos, Brett & Co., Ltd | DRP-10037 | Aug 6, 2030 | |
ClotimaxClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Magbro Healthcare Pvt. Ltd.India | Sigma Medical Solution Trading Co. Inc.Importer: Pharmakon Biotec Inc. | DRP-10878-06 | Dec 10, 2026 | |
CLOTINCLOPIDOGREL | 75 MG FILM-COATED TABLETALU - ALU BLISTER PACK X 10'S BOX OF 30'S | Rx | J.M. TOLMANN LABORATORIES INC.Philippines | CHMI PHARMA, INC. | DRP-2470-14 | Feb 2, 2030 | |
ClotizClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu-Alu Blister pack x 10's (Box of 30's and 100's) | Rx | Hizon Laboratories, Inc.Philippines | Chira Pharmaceuticals, Inc. | DRP-6838-01 | Nov 17, 2029 | |
ClotstopClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Magbro Healthcare Pvt. Ltd.India | One Technodrug Life Sciences Inc.Importer: Pharmakon Biotec Inc. | DRP-10878-08 | Dec 10, 2026 | |
ClovasClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Solvang Pharmaceuticals, Inc. | DRP-4028 | Oct 22, 2031 | |
ClovelClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/PVC Blister Pack of 10's (Box of 100's) | Rx | J. Duncan Healthcare Pvt. Ltd.India | SEA-King Pharma Inc.Importer: Grovic Pharma Inc. | DRP-12391-2 | Jul 13, 2027 | |
ClovertaClopidogrel | 75 mg Film – Coated TabletAlu/Alu Blister Pack x 10’s Box of 50’s and 100’s | Rx | Stallion Laboratories Pvt. Ltd.India | HLM Pharmaceutical Inc.Importer: Suhitas Pharmaceuticals Inc.Trader: Mac Heal Laboratories Ltd. | DRP-1791-05 | Aug 17, 2029 | |
ClovertaClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | Zim Laboratories LimitedIndia | HLM Pharmaceutical Inc.Importer: Medinova Pharmaceutical Inc. | DRP-9166-11 | Sep 22, 2031 | |
ClovixaClopidogrel (As Bisulfate) | 75mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | The ACME Laboratories LimitedBangladesh | Bell-Kenz Pharma Inc.Importer: Euro Generics International Phils., Inc. | DRP-2213 | Aug 12, 2027 | |
ColifeClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s and 100’s) | Rx | Fredun Pharmaceuticals LimitedIndia | Life And Health Source Pharmaceutical Distribution Co.Importer: AMB HK Enterprises Inc. | DRP-12515-01 | Aug 25, 2027 | |
ColifeClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Globela Pharma Private LimitedIndia | Life and Health Source Pharmaceutical Distribution Co.Importer: AMB HK Enterprises Inc. | DRP-13933-02 | May 18, 2028 | |
CombiplateClopidogrel (as bisulfate) | 75 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | Hebei Tiancheng Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-16511 | Apr 7, 2030 | |
CONTRACLOTCLOPIDOGREL | 75 MG FILM-COATED TABLETALU / ALU BLISTER PACK X 10'S (BOX OF 30'S) | Rx | J.M. Tolmann Laboratories Inc.Philippines | Medirich Pharma Distribution Corp | DRP-2470-11 | Feb 2, 2030 | |
CopideClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 30's and 100's) | Rx | Globela Pharma Private LimitedIndia | PhilRx Pharma Inc. | DRP-11594 | Mar 31, 2032 | |
CopideClopidogrel (as bisulfate) | 75mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Globela Pharma Private LimitedIndia | AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc. | DRP-13489 | Feb 27, 2028 | |
CorpletClopidogrel (as Bisulfate) | 75mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | MEPRO PHARMACEUTICALS PRIVATE LIMITEDIndia | MC GRAW PHARMA INC.Importer: MEDETHIX INC. | DRP-8514 | Nov 22, 2027 | |
DeplattClopidogrel (as Bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Torrent Pharmaceuticals LimitedIndia | Torrent Pharma Philippines, Inc. | DRP-2681 | Dec 21, 2029 | |
DiapidClopidogrel (as Bisulfate) | 75 mg TabletAluminum Strip Foil of 4's Box of 100's | Rx | Diamond Laboratories Inc.Philippines | Full Health International Pharma | DRP-7604 | Apr 11, 2029 | |
DomidonClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/PVC Blister pack x 10's (Box of 10's) | Rx | BDA Healthcare Pvt. Ltd.India | Orange Biotec Inc. | DRP-15765 | Sep 12, 2029 | |
DopirelClopidogrel | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30's) | Rx | Zim Laboratories LimitedIndia | Suhitas Pharmaceuticals Inc.Trader: PSA International (Export Division of PSA chemicals & Pharmaceuticals Pvt. Ltd. | DRP-1674 | Oct 28, 2029 | |
DorellClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 100's | Rx | Stallion Laboratories Pvt. Ltd.India | Starpharm, Inc.Importer: Ambica International Corporation | DRP-2672-03 | Jan 4, 2029 | |
DrhelClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | Diafarm Inc.Importer: Ambica International Corporation | DRP-2672-18 | Jan 4, 2029 | |
FedgrelClopidogrel (as bisulfate) | 75mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Globela Pharma Private LimitedIndia | AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc. | DRP-13933 | May 18, 2028 | |
FlamdovixClopidogrel | 75 mg TabletAlu/Alu Blister Pack x 10’s (Box of 100's) | Rx | Flamingo Pharmaceuticals Ltd.India | Hexagon Pharmaceuticals | DRP-2140 | Oct 26, 2029 | |
FlavixClopidogrel | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Centurion Laboratories Pvt. Ltd.India | Steinbach Products Inc.Importer: Philgen Pharmaceuticals Inc. | DRP-11057-01 | Jan 20, 2027 | |
GopidClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 100's | Rx | Stallion Laboratories Pvt. Ltd.India | Applied Pharmaceutical Distribution IncImporter: Ambica International Corporation | DRP-2672-02 | Jan 4, 2029 | |
GrelpillClopidogrel (As Bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10 Blister packs x 10 Tablets) | Rx | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-13205 | Dec 28, 2027 | |
GropidClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/PVC Blister Pack of 10's (Box of 100's) | Rx | J. Duncan Healthcare Pvt. Ltd.India | GROVIC PHARMA INC. | DR-XY45960 | Jul 13, 2027 | |
GropidClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/PVC Blister Pack of 10's (Box of 100's) | Rx | J. Duncan Healthcare Pvt. Ltd.India | Grovic Pharma Inc. | DRP-12391 | Jul 13, 2027 | |
HemaclidClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's ); Alu/Alu Blister Pack x 10's (Box of 50's & 100's) | Rx | Magbro Healthcare Pvt. Ltd.India | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-10878-3 | Dec 10, 2026 | |
HemaflowClopidogrel | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10 's Box of 30's | Rx | Hovid BerhadMalaysia | Hovid Inc. | DR-XY36848 | Oct 21, 2029 | |
HemoflowClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's and Box of 100's) | Rx | S Kant Healthcare Ltd.India | New Seammed IncImporter: Medinova Pharmaceutical Inc. | DRP-18339-03 | Jun 16, 2031 | |
HemoflowClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s and 100’s) | Rx | Zim Laboratories LimitedIndia | New Seammed Inc.Importer: Medinova Pharmaceutical Inc. | DRP-9166-10 | Oct 30, 2031 | |
KhrizvixClopidogrel (as bisulfate) | 75mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 30's) | Rx | Fredun Pharmaceuticals Ltd.India | Khriz Pharma Trading Inc. | DRP-11514 | Mar 30, 2027 | |
KlopiClopidogrel (as Bisulfate) | 75 mg Film-Coated TabletAlu/Clear PVC/PVDC Blister Pack x 10’s (Box of 30's and 50's) | Rx | Kusum Healthcare Private LimitedIndia | Kusum Healthcare Private Limited Branch Office | DRP-11521 | Mar 12, 2031 | |
KlopideClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Ultramed Pharma, Inc.Trader: Solvang Pharmaceuticals, Inc. | DRP-4028-04 | Aug 19, 2031 | |
KlopidoClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Totalcare Pharma Inc.Trader: Solvang Pharmaceuticals, Inc. | DRP-4028-01 | Jul 20, 2031 | |
LifegrelClopidogrel (as bisulfate) | 75 mg Film-Coated TabletClear PVC/Alu Blister x 10’s Box of 100’s | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India | Radbuster Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-3126-03 | Jul 14, 2029 | |
LopimaxClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Kyung Dong Pharm Co., Ltd.Republic of Korea | Bliss Pharma Distribution and Consultancy Corp. | DRP-3837 | Dec 22, 2026 | |
LoprelClopidogrel | 75 mg Film-Coated TabletAlu-Alu Blister Pack X 10's Box of 30's | Rx | J.M. Tolmann Laboratories Inc.Philippines | Medirich Pharma Distribution Corp. | DRP-2470-08 | Feb 2, 2030 | |
MedogrelClopidogrel (as Bisulfate) | 75 mg Film coated tabletAlu/Alu Blister Pack x 10's (Box of 10's, 30's and 100's) | Rx | Medico Remedies LimitedIndia | Medethix, Inc. | DRP-4538 | Jul 23, 2028 | |
Milopid 75Clopidogrel | 75 mg Film – Coated TabletAlu/Alu Blister Pack x 10’s (Box of 50’s and 100’s) | Rx | Stallion Laboratories Pvt. Ltd.India | Jjysrinn Trading Inc.Importer: Suhitas Pharmaceuticals Inc.Trader: Mac Heal Laboratories Ltd. | DRP-1791-06 | Aug 17, 2029 | |
MUGRELClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/PVC Blister Pack of 10's (Box of 100's) | Rx | J. Duncan Healthcare Pvt. Ltd.India | Multigro Healthcare Inc.Importer: Grovic Pharma Inc. | DRP-12391-01 | Jul 13, 2027 | |
NavorelClopidogrel (as bisulfate) | 75 mg Film-Coated TabletClear PVC/Alu Blister x 10’s (Box of 100’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India | Ambicare Pharmaceuticals, Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-3126-01 | Jul 14, 2029 | |
NeoclopidClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | GX International, Inc.Importer: Ambica International Corporation | DRP-2672-15 | Jan 4, 2029 | |
NOCLOTCLOPIDOGREL | 75 MG FILM-COATED TABLETAlu-Alu Blister Pack x 10's (Box of 30's) | Rx | J.M. TOLMANN LABORATORIES INC.Philippines | WESTFIELD PHARMACEUTICALS, INC. | DRP-2470-12 | Feb 5, 2030 | |
NoklotClopidogrel (as bisulfate) | 75 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's); Alu/Alu Blister Pack x 10's (Box of 10's) as Physician's Sample | Rx | Cadila Healthcare LimitedIndia | Zydus Healthcare Philippines, Inc. | DRP-11517 | Apr 1, 2027 | |
NoklotClopidogrel (as Bisulfate) | 75 mg Film-Coated TabletAlu/Clear PVC Blister Pack by 10's (Box of 30's) | Rx | Cadila Healthcare LimitedIndia | Zydus Healthcare Philippines, Inc. | DRP-881 | May 26, 2029 | |
NoneClopidogrel | 75 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | Centurion Laboratories Pvt. Ltd.India | TGP Pharma Inc.Importer: Philgen Pharmaceuticals, Inc | DRP 11057-02 | Jan 20, 2027 | |
NoneClopidogrel | 75 mg Film Coated TabletAlu / Alu Blister Pack x 10's (Box of 100's) | Rx | Centurion Laboratories Pvt. Ltd.India | Better Option Pharmaceuticals, Inc.Importer: Philgen Pharmaceuticals, Inc. | DRP-11057-05 | Jan 20, 2027 | |
NoneClopidogrel (as bisulfate) | 75 mg Film Coated TabletAlu/Alu Strip Foil x 4's (Box of 100's); Alu/Alu Strip Foil x 4's (Box of 8's) [Physician's Sample] | Rx | Interphil Laboratories, Inc.Philippines | St. Joseph Drugstore | DRP-3793-04 | Jun 13, 2028 | |
NoneClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Dyna Drug Corporation | DR-XY38777 | Nov 19, 2030 | |
NoneClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | Rx | Hizon Laboratories, Inc.Philippines | — | DR-XY43711 | Sep 17, 2029 | |
NoneClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's, 50's and 100's) | Rx | Magbro Healthcare Pvt. Ltd.India | Alkem Laboratories CorporationImporter: Pharmakon Biotec Inc. | DRP-10878-02 | Dec 10, 2026 | |
NoneClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu-Alu Blister Pack x 7's (Box of 14's) | Rx | Sandoz Private LimitedIndia | Ritemed Phils., Inc.Importer: Sandoz Philippines Corporation | DRP-2123-04 | Oct 14, 2029 | |
NoneCLOPIDOGREL | 75 MG FILM-COATED TABLETALU - ALU BLISTER PACK X 10'S (BOX OF 30'S) | Rx | J.M. TOLMANN LABORATORIES INC.Philippines | — | DRP-2470 | Feb 2, 2030 | |
NoneClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | TGP Pharma Inc.Importer: Ambica International Corporation | DRP-2672-14 | Jan 4, 2029 | |
NoneClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | OEP Philippines, Inc.Importer: Ambica International Corporation | DRP-2672-16 | Jan 4, 2029 | |
NoneClopidogrel (as Bisulfate) | 75 mg Film-Coated TabletClear PVC/Alu Blister Pack x 10’s (Box of 100's) | Rx | Akums Drugs & Pharmaceuticals Ltd.India | Actimed, Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-3126-02 | Jul 14, 2029 | |
NoneClopidogrel (as bisulfate) | 75 mg Film-Coated TabletClear PVC/Alu Blister Pack x 10’s (Box of 100’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India | Diafarm, Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-3126-07 | Jul 14, 2029 | |
NoneClopidogrel Bisulfate | 75 mg Film-Coated TabletFoil Strip x 10's Box of 50's | Rx | Ajanta Pharma LimitedIndia | RITEMED PHILS., INC. | DRP-3168 | Jul 10, 2029 | |
NoneClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu Foil Strip x 4''s (Box of 100's) | Rx | Interphil Laboratories, Inc.Philippines | ROSE PHARMACY, INCORPORATED | DRP-3793-01 | Jun 13, 2028 | |
NoneClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu Foil Strip x 4's (Box of 100's) | Rx | Interphil Laboratories, Inc.Philippines | Neodrug Inc. | DRP-3793-03 | Jun 13, 2028 | |
NoneClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100’s) | Rx | Stallion Laboratories Pvt. Ltd.India | PharmaVital Corp.Importer: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd. | DRP-4698-02 | Sep 13, 2028 | |
NoneClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Mediwin PharmaceuticalsIndia | Dynasty PharmaceuticalsImporter: Ambica International Corporation | DRP-6560-01 | Oct 10, 2030 | |
NoneClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's, 50's and 100's) | Rx | Hizon Laboratories, Inc.Philippines | — | DRP-6838 | Nov 17, 2029 | |
NoneClopidogrel (as Bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 30's | Rx | Mepro Pharmaceutical Private LimitedIndia | Actimed, Inc.Importer: Medethix, Inc. | DRP-8514-01 | Nov 22, 2027 | |
NoneClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | Zim Laboratories LimitedIndia | Qualifirst Health, Inc.Importer: Medinova Pharmaceutical, Inc. | DRP-9166-14 | Sep 21, 2030 | |
NoneClopidogrel (as bisulfate) | 75 mg TabletPA/Alu/PVC Blister Pack x 14's | Rx | Sanofi Winthrop IndustrieFrance | Importer: Sanofi Pasteur Inc. | DR-XY32673 | Mar 12, 2031 | |
NoneClopidogrel (as bisulfate) | 75 mg TabletAlu/Alu Blister Pack x 10’s Box of 30’s | Rx | Sun Pharmaceuticals Industries LimitedIndia | Importer: Sun Pharma Philippines, Inc. | DRP-2008 | Mar 31, 2030 | |
NoneClopidogrel (as bisulfate) | 75mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | Mepro Pharmaceuticals Private LimitedIndia | Vivilon Pharmaceuticals Inc.Importer: Medethix, Inc. | DRP-8514-03 | Nov 22, 2027 | |
NoneClopidogrel (as Bisulfate) | 75mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | Mepro Pharmaceuticals Private LimitedIndia | Uniqure Pharma Inc.Importer: Medethix, Inc. | DRP-8514-05 | Nov 22, 2027 | |
NorplatClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 28's) | Rx | Getz Pharma Pvt. Ltd.Pakistan | Getz Pharma (Phils.), Inc. | DR-XY32200 | Jul 30, 2030 | |
NuclotClopidogrel | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | Centurion Laboratories Pvt. Ltd.India | Vitalife Pharma & Medical Supply IncImporter: Philgen Pharmaceuticals, Inc. | DRP-11057-04 | Jan 20, 2027 | |
OP-ReduclotClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Globela Pharma Private LimitedIndia | Orient Pearl Med Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP-13933-1 | May 18, 2028 | |
OragrelClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's, 50's and 100's) | Rx | Zim Laboratories LimitedIndia | Suhitas Pharmaceuticals Inc.Importer: Orange Biotec Inc.Trader: Amegh Pharma Pvt. Ltd. | DRP-3250-02 | Sep 20, 2031 | |
PharmagrelClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | 228 Pharma TradingImporter: Ambica International Corporation | DRP-2672-10 | Jan 4, 2029 | |
PidogrelClopidogrel | 75 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Centurion Laboratories Pvt. Ltd.India | Meedpharma Medical Supplies & Equipment DistributorImporter: Philgen Pharmaceuticals Inc | DRP-11057-03 | Jan 20, 2027 | |
PigrelClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Philippine Home Pharmaceuticals | DR-XY39510 | May 27, 2031 | |
PlagerineClopidogrel (as Bisulfate) | 75 mg Film Coated tabletAlu-Alu Blister Pack x 10's Box of 30's | Rx | Micro labs LimitedIndia | Brown & Burk Philippines Inc. | DRP-948 | Jan 7, 2028 | |
PlasmablocClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Magbro Healthcare Pvt. Ltd.India | Pharmakon Biotec, Inc. | DRP-10878 | Dec 10, 2026 | |
Plat-LowClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30's) | Rx | Globela Pharma Private LimitedIndia | CCL Pharmaceuticals (Philippines), Inc.Importer: AMB HK Enterprises Inc. | DRP-13489-01 | Feb 27, 2028 | |
PlatcloClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu-Alu Blister pack x 14's (Box of 1's) | Rx | Medreich Limited (Unit 3)India | Metro Drug, Inc.Importer: Paradigm Pharma (Philippines) Corporation | DRP-15191 | May 22, 2029 | |
PlatexanClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu blister pack x 10's (box of 30's and 100's) | Rx | Samjin Pharmaceutical Co., Ltd.Korea | Patriot Pharmaceuticals Corporation. | DR-XY49142 | Jul 30, 2029 | |
PlatexanClopidogrel (as bisulfate) | 75 mg tabletAlu/Alu Blister Pack x 10's (Box of 30's); Alu/Alu Blister Pack x 15's (Box of 15's) | Rx | Apotex, Inc.Canada | Patriot Pharmaceuticals Corporation | DR-XY35075 | Oct 29, 2028 | |
PlatikonClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Healer's Lab (Unit II)India | Pharmakon Biotec, Inc. | DRP-16473 | Mar 20, 2030 | |
PlatzClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | The Cathay YSS Distributors Co., IncImporter: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd. | DRP-4698-01 | Sep 13, 2028 | |
PlavicarClopidogrel (as bisulfate) | 75 mg Film Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's and 100's) | Rx | Hebei Tiancheng Pharmaceutical Co., Ltd.China | PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP-15451-01 | Jul 11, 2029 | |
PlavidoClopidogrel (as Bisulfate) | 75mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc. | DRP-12515 | Aug 25, 2027 | |
PlavihexClopidogrel | 75 mg TabletAlu/Alu Blister Pack x 10’s (Box of 100's) | Rx | Flamingo Pharmaceuticals Ltd.India | Hexagon Pharmaceuticals | DRO-2140-01 | Oct 26, 2029 | |
PlavixClopidogrel (As Bisulfate) | 300 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Sanofi Winthrop IndustrieFrance | Importer: Sanofi-Aventis Philippines, Inc. | DR-XY37405 | Nov 17, 2027 | |
PlavixClopidogrel (As Bisulfate) | 75 mg Film Coated TabletAlu/Alu Blister Pack x 14's (Box of 14's) | Rx | Sanofi Winthrop IndustrieFrance | Importer: Sanofi-Aventis Philippines, Inc. | DRP-5643 | Oct 7, 2027 | |
PlogrelClopidogrel Bisulfate | 75 mg Film-Coated TabletFoil Strip x 10's (Box of 50's) | Rx | Ajanta Pharma LimitedIndia | UNILAB, INC. | DRP-3168-01 | Jul 16, 2029 | |
PlogrilClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's); Alu/Clear PVC Blister Pack x 10's (Box of 30's) | Rx | Drugmaker's Laboratories Inc.Philippines | — | DRP-2267 | Mar 29, 2032 | |
PrimevixClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's, 50's and 100's) | Rx | Magbro Healthcare Pvt. Ltd.India | Life and Health Source Pharmaceutical Distribution Co.Importer: Pharmakon Biotec Inc. | DRP-10878-09 | Dec 10, 2026 | |
PurilClopidogrel (As Bisulfate) | 75 mg Film -Coated TabletAlu/Alu Cold Forming Blister Pack x 10's (Box of 30's) | Rx | USV Private LimitedIndia | USV Pharma Philippines Inc. | DR-XY49760 | Jul 2, 2031 | |
RetaplavClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 10's, 30's, 50's and 100's) | Rx | BDA Healthcare Pvt. Ltd.India | Reta DrugImporter: Orange Biotec Inc. | DRP-15765-01 | Sep 12, 2029 | |
SaphlopidClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 100's | Rx | Sapphire Lifesciences Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-7384 | Oct 4, 2027 | |
SAPHLOPID-GE75Clopidogrel (As Bisulfate) | 75 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Genom Biotech Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-18235 | Jun 2, 2031 | |
ShegrelClopidogrel (as Bisulfate) | 75 mg Film-Coated TabletAlu/White PVC Blister Pack x 10's (Box of 100's) | Rx | Medisure Laboratories Pakistan (Pvt.) LimitedPakistan | Malyka International Trading Corp.Importer: Accesspoint International Trading Inc. | DRP-6042-01 | Apr 16, 2037 | |
SkygrelClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | Qualifirst Health Inc.Importer: Ambica International Corporation | DRP-2672-07 | Jan 4, 2029 | |
SyclopidClopidogrel (as bisulfate) | 6 mg/mL Syrup (Oral Drops)Alu/PVDC/PVC White Opaque Blister Pack x 10's Box of 100's; Alu/PVDC/PVC White Opaque Blister Pack x 7's Box of 28's | Rx | Sydenham Laboratories, Inc.Philippines | Sydenham Pharmaceuticals, Inc. | DRP-2202 | Dec 1, 2029 | |
SydogrelClopidogrel (as bisulfate) | 75 mg Film Coated TabletAlu/Alu BlisterPack x 10's (Box of 100's) | Rx | The Madras PharmaceuticalsIndia | Synergen Pharma Inc.Trader: Synergen Asia Pte. Ltd. | DRP-6062 | Sep 3, 2028 | |
T-ClotClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Magbro Healthcare Pvt. Ltd.India | Teramedix Pharma Trading Inc. | DRP-15738 | Sep 11, 2029 | |
ThrombicareClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Vitalink Health Products, Inc.Trader: Solvang Pharmaceuticals, Inc. | DRP-4028-02 | Jul 14, 2031 | |
TimibestClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Magbro Healthcare Pvt. Ltd.India | Littman Drug CorporationImporter: Pharmakon Biotec Inc.Trader: Sarva Pharmaceuticals Pvt. Ltd. | DRP-10878-01 | Dec 10, 2026 | |
TridogrelClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 100's | Rx | Stallion Laboratories Pvt. Ltd.India | RSG Pharma TradingImporter: Ambica International Corporation | DRP-2672-04 | Jan 4, 2029 | |
TrombixClopidogrel (as bisulfate) | 75 mg Film-Coated TabletBlister Pack x 14’s (Box of 14’s) | Rx | Standard Chem. & Pharm. Co., LtdChina | Phil Pharmawealth, Inc. | DR-XY38329 | Aug 4, 2030 | |
UnbrandedClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 10's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Dr. Zen’s Research, Inc. | DR-XY38668 | Oct 20, 2030 | |
UnbrandedClopidogrel | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's in a box | Rx | Ferozsons Laboratories LimitedPakistan | First Global Trading Corporation | DR-XY44799 | Sep 3, 2031 | |
UnbrandedClopidogrel | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | Centurion Laboratories Pvt. Ltd.India | Philgen Pharmaceuticals Inc. | DRP-11057 | Jan 20, 2032 | |
UnbrandedClopidogrel (as Bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s Box of 100’s | Rx | XL Laboratories Pvt. Ltd.India | RiteMed Phils., Inc.Importer: Ambica International Corporation | DRP-1885-02 | Sep 8, 2029 | |
UnbrandedClopidogrel (as bisulfate) | 75 mg Film-Coated TabletClear PVC/Alu Blister Pack x 10’s Box of 100’s | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India | RiteMED Phils., Inc.Importer: Ambica International Corporation | DRP-3126-04 | Jul 14, 2029 | |
UnbrandedClopidogrel (as bisulfate) | 75 mg Film-Coated TabletClear PVC/Alu Blister Pack x 10’s Box of 100’s | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India | International Pharmaceuticals, Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-3126-05 | Jul 14, 2029 | |
UnbrandedClopidogrel (as bisulfate) | 75 mg Film-Coated TabletClear PVC/Alu Blister Pack x 10’s (Box of 100’s) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant I-Solid Oral Dosage Facility)India | South Star DrugImporter: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-3126-06 | Jul 14, 2029 | |
UnbrandedClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Lloyd Laboratories, Inc.Philippines | Watsons Personal Care Stores (Philippines), Inc.Trader: Solvang Pharmaceuticals, Inc. | DRP-4028-03 | Jul 30, 2031 | |
UnbrandedClopidogrel (as Bisulfate) | 75mg Film-Coated Tablet | Rx | — | TGP Pharma Inc. | DRP-2267-03 | Mar 29, 2027 | |
ValdonClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/ PVC Blister Pack x 10’s (Box of 30’s and 100’s) | Rx | Hebei Tiancheng Pharmaceutical Co., Ltd.China | Corbridge Group Phils., Inc.Importer: Amb Hk Enterprises Inc. | DRP-15451-02 | Jul 11, 2029 | |
VasclorixClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's, 50's, and 100's) | Rx | Magbro Healthcare Pvt. Ltd.India | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-10878-12 | Dec 10, 2026 | |
75 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | AKUMS DRUGS & PHARMACEUTICALS LTD.India | VE PHARMA INC.Trader: Vexxa Lifesciences Pvt. Ltd | DR-XY44065 | Jan 29, 2030 | ||
VivelonClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's) | Rx | Micro Labs LimitedIndia | ADP Pharma CorporationImporter: Brown & Burk Phils., Inc. | DRP-948-01 | Jan 7, 2028 | |
XerevoClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | Miraculin Pharma Inc.Importer: Ambica International Corporation | DRP-2672-08 | Jan 4, 2029 | |
ZandropilClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 100's | Rx | Stallion Laboratories Pvt. Ltd.India | Altomed Pharmaceuticals, Inc.Importer: Ambica International Corporation | DRP-2672-12 | Jan 4, 2029 | |
ZeroclotClopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 100's | Rx | Stallion Laboratories Pvt. Ltd.India | Primera Pharma CorporationImporter: Ambica International Corporation | DRP-2672-01 | Jan 4, 2029 | |
(no brand name)Clopidogrel (as bisulfate) | 75 mg Film Coated TabletAlu/Alu Blister Pack x 7's (Box of 28's) | Rx | Bafna Pharmaceuticals LimitedIndia | Medethix, Inc. | DRP-16366 | Feb 20, 2030 | |
(no brand name)Clopidogrel (as bisulfate) | 75 mg Film Coated TabletAlu/Alu Blister Pack x 14's (Box of 14's) | Rx | Sanofi Winthrop IndustrieFrance | Philusa CorporationImporter: Sanofi-Aventis Philippines, Inc. | DRP-5643-01 | Oct 7, 2027 | |
(no brand name)Clopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Centurion Laboratories Pvt. Ltd.India | Philgen Pharmaceuticals, Inc. | DRP-11515 | Apr 1, 2027 | |
(no brand name)Clopidogrel (As Bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10 Blister packs x 10 Tablets) | Rx | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-13204 | Dec 28, 2027 | |
(no brand name)Clopidogrel (as bisulfate) | 75 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant I - Solid Oral Dosage Facility)India | Ambica International Corporation.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-14741 | Dec 20, 2028 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS 75 mg tablets: Pink, round, biconvex, film-coated tablets debossed with "75" on one side and "1171" on the other 300 mg tablets: Pink, oblong, film-coated tablets debossed with "300" on one side and "1332" on the other Film-coated tablets: 75 mg, 300 mg (3)
Warnings/Precautions
The boxed warning is shown at the top of this page.
- CYP2C19 inhibitors: Avoid concomitant use of omeprazole or esomeprazole. (5.1)
- Bleeding: Plavix increases risk of bleeding. (5.2)
- Discontinuation: Premature discontinuation increases risk of cardiovascular events. Discontinue 5 days prior to elective surgery that has a major risk of bleeding. (5.3)
- Thrombotic thrombocytopenic purpura (TTP) has been reported. (5.4)
- Cross-reactivity among thienopyridines has been reported. (5.5)
5.1 Diminished Antiplatelet Activity in Patients with Impaired CYP2C19 Function
5.1 Diminished Antiplatelet Activity in Patients with Impaired CYP2C19 Function Clopidogrel is a prodrug. Inhibition of platelet aggregation by clopidogrel is achieved through an active metabolite. The metabolism of clopidogrel to its active metabolite can be impaired by genetic variations in CYP2C19 [see Boxed Warning].
The metabolism of clopidogrel can also be impaired by drugs that inhibit CYP2C19, such as omeprazole or esomeprazole. Avoid concomitant use of Plavix with omeprazole or esomeprazole because both significantly reduce the antiplatelet activity of Plavix [see Drug Interactions (7.1)].
5.2 General Risk of Bleeding
5.2 General Risk of Bleeding P2Y12 inhibitors (thienopyridines), including Plavix, increase the risk of bleeding. P2Y12 inhibitors (thienopyridines), inhibit platelet aggregation for the lifetime of the platelet (7–10 days). Because the half-life of clopidogrel's active metabolite is short, it may be possible to restore hemostasis by administering exogenous platelets; however, platelet transfusions within 4 hours of the loading dose or 2 hours of the maintenance dose may be less effective.
Use of drugs that induce the activity of CYP2C19 would be expected to result in increased drug levels of the active metabolite of clopidogrel and might potentiate the bleeding risk. As a precaution, avoid concomitant use of strong CYP2C19 inducers [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)]. Risk factors for bleeding include concomitant use of other drugs that increase the risk of bleeding (e.g., anticoagulants, antiplatelet agents, and chronic use of NSAIDs) [see Drug Interactions (7.4, 7.5, 7.6, 7.7)].
5.3 Discontinuation of Plavix
5.3 Discontinuation of Plavix Discontinuation of Plavix increases the risk of cardiovascular events. If Plavix must be temporarily discontinued (e.g., to treat bleeding or for surgery with a major risk of bleeding), restart it as soon as possible. When possible, interrupt therapy with Plavix for five days prior to such surgery.
Resume Plavix as soon as hemostasis is achieved.
5.4 Thrombotic Thrombocytopenic Purpura (TTP)
5.4 Thrombotic Thrombocytopenic Purpura (TTP) TTP, sometimes fatal, has been reported following use of Plavix, sometimes after a short exposure (<2 weeks). TTP is a serious condition that requires urgent treatment including plasmapheresis (plasma exchange). It is characterized by thrombocytopenia, microangiopathic hemolytic anemia (schistocytes [fragmented RBCs] seen on peripheral smear), neurological findings, renal dysfunction, and fever [see Adverse Reactions (6.2)].
5.5 Cross-Reactivity
5.5 Cross-Reactivity among Thienopyridines Hypersensitivity including rash, angioedema or hematologic reaction has been reported in patients receiving Plavix, including patients with a history of hypersensitivity or hematologic reaction to other thienopyridines [see Contraindications (4.2) and Adverse Reactions (6.2)].
Drug interactions
- CYP2C19 inducers: Increases levels of clopidogrel active metabolite and increases platelet inhibition. (7.1)
- Opioids: Decreased exposure to clopidogrel. Consider use of parenteral antiplatelet agent. (7.3)
- Nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, selective serotonin and serotonin norepinephrine reuptake inhibitors (SSRIs, SNRIs): Increases risk of bleeding. (7.4, 7.5, 7.6)
- Other Antiplatelet Agents: Increases the risk of bleeding due to an additive effect. (7.7)
- Repaglinide (CYP2C8 substrates): Increases substrate plasma concentrations. (7.8)
7.1 CYP2C19 Inducers
7.1 CYP2C19 Inducers Since clopidogrel is metabolized to its active metabolite partly by CYP2C19, use of drugs that induce the activity of this enzyme would be expected to result in increased drug levels of the active metabolite of clopidogrel. Rifampin strongly induces CYP2C19 resulting to both an increase level of clopidogrel active metabolite and platelet inhibition, which in particular might potentiate the risk of bleeding.
As a precaution, avoid concomitant use of strong CYP2C19 inducers [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].
7.2 CYP2C19 Inhibitors
7.2 CYP2C19 Inhibitors Clopidogrel is metabolized to its active metabolite in part by CYP2C19. Concomitant use of drugs that inhibit the activity of this enzyme results in reduced plasma concentrations of the active metabolite of clopidogrel and a reduction in platelet inhibition [see Warnings and Precautions (5.1)]. Omeprazole or Esomeprazole Avoid concomitant use of Plavix with omeprazole or esomeprazole.
In clinical studies, omeprazole was shown to reduce significantly the antiplatelet activity of Plavix when given concomitantly or 12 hours apart. A similar reduction in antiplatelet activity was observed with esomeprazole when given concomitantly with Plavix. Dexlansoprazole, lansoprazole, and pantoprazole had less effect on the antiplatelet activity of Plavix than did omeprazole or esomeprazole [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].
7.3 Opioids
7.3 Opioids As with other oral P2Y 12 inhibitors, coadministration of opioid agonists delay and reduce the absorption of clopidogrel, presumably because of slowed gastric emptying, resulting in reduced exposure to its metabolites [see Clinical Pharmacology (12.3)]. Consider the use of a parenteral antiplatelet agent in acute coronary syndrome patients requiring coadministration of morphine or other opioid agonists.
7.4 Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Coadministration of Plavix
7.4 Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Coadministration of Plavix and NSAIDs increases the risk of gastrointestinal bleeding.
7.5 Warfarin (CYP2C9 Substrates)
7.5 Warfarin (CYP2C9 Substrates) Although the administration of clopidogrel 75 mg per day did not modify the pharmacokinetics of S-warfarin (a CYP2C9 substrate) or INR in patients receiving long-term warfarin therapy, coadministration of Plavix with warfarin increases the risk of bleeding because of independent effects on hemostasis. However, at high concentrations in vitro, clopidogrel inhibits CYP2C9.
7.6 SSRIs and SNRIs
7.6 SSRIs and SNRIs Since selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) affect platelet activation, the concomitant administration of SSRIs and SNRIs with clopidogrel may increase the risk of bleeding.
7.7 Other Antiplatelet Agents
7.7 Other Antiplatelet Agents Coadministration of antiplatelet agents increase the risk of bleeding due to an additive effect. Promptly evaluate any signs or symptoms of blood loss if patients are treated concomitantly with other antiplatelet agents [see Warnings and Precautions (5.2)].
7.8 Repaglinide (CYP2C8 Substrates)
7.8 Repaglinide (CYP2C8 Substrates) The acyl-β-glucuronide metabolite of clopidogrel is a strong inhibitor of CYP2C8. Plavix can increase the systemic exposure to drugs that are primarily cleared by CYP2C8, thereby needing dose adjustment and appropriate monitoring. Plavix increased repaglinide exposures by 3.9-fold to 5.1-fold [see Clinical Pharmacology (12.3)].
Avoid concomitant use of repaglinide with Plavix. If concomitant use cannot be avoided, initiate repaglinide at 0.5 mg before each meal and do not exceed a total daily dose of 4 mg. Increased frequency of glucose monitoring may be required during concomitant use.
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
The active metabolite is formed mostly by CYP2C19 with contributions from several other CYP enzymes, including CYP1A2, CYP2B6 and CYP3A.
Drug Interactions Effect of other drugs on Plavix Clopidogrel is metabolized to its active metabolite in part by CYP2C19.
CYP2C19 inducers Concomitant use of strong inducers of CYP2C19 results in increased plasma concentration of the active metabolite of clopidogrel and an increase in platelet inhibition.
CYP2C19 inhibitors Concomitant use of certain inhibitors of this enzyme results in reduced plasma concentrations of the active metabolite of clopidogrel and a reduction in platelet inhibition.
Effect of Plavix on other drugs In vitro studies have shown that the glucuronide metabolite of clopidogrel is a strong inhibitor of CYP2C8.
7 DRUG INTERACTIONS CYP2C19 inducers: Increases levels of clopidogrel active metabolite and increases platelet inhibition.
( 7.7 ) Repaglinide (CYP2C8 substrates): Increases substrate plasma concentrations.
( 7.8 ) 7.1 CYP2C19 Inducers Since clopidogrel is metabolized to its active metabolite partly by CYP2C19, use of drugs that induce the activity of this enzyme would be expected to result in increased drug levels of the active metabolite of clopidogrel.
Adverse reactions
- The following serious adverse reactions are discussed below and elsewhere in the labeling: Bleeding [see Warnings and Precautions (5.2)] Thrombotic thrombocytopenic purpura [see Warnings and Precautions (5.4)] Bleeding, including life-threatening and fatal bleeding, is the most commonly reported adverse reaction. (6.1)
- To report SUSPECTED ADVERSE REACTIONS, contact sanofi-aventis U.S. LLC at 1-800-633-1610 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions and durations of follow-up, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Plavix has been evaluated for safety in more than 54,000 patients, including over 21,000 patients treated for one year or more.
The clinically important adverse reactions observed in trials comparing Plavix plus aspirin to placebo plus aspirin and trials comparing Plavix alone to aspirin alone are discussed below. Bleeding CURE In CURE, Plavix use with aspirin was associated with an increase in major bleeding (primarily gastrointestinal and at puncture sites) compared to placebo with aspirin (see Table 1).
The incidence of intracranial hemorrhage (0.1%) and fatal bleeding (0.2%) were the same in both groups. Other bleeding events that were reported more frequently in the clopidogrel group were epistaxis, hematuria, and bruise. The overall incidence of bleeding is described in Table 1. Table 1: CURE Incidence of Bleeding Complications (% patients) Event Plavix (+ aspirin) (n=6259) Placebo (+ aspirin) (n=6303) Major bleeding Life-threatening and other major bleeding. 3.7 2.7 Life-threatening bleeding 2.2 1.8 Fatal 0.2 0.2 5 g/dL hemoglobin drop 0.9 0.9 Requiring surgical intervention 0.7 0.7 Hemorrhagic strokes 0.1 0.1 Requiring inotropes 0.5 0.5 Requiring transfusion (≥4 units) 1.2 1.0 Other major bleeding 1.6 1.0 Significantly disabling 0.4 0.3 Intraocular bleeding with significant loss of vision 0.05 0.03 Requiring 2–3 units of blood 1.3 0.9 Minor bleeding Led to interruption of study medication. 5.1 2.4 COMMIT In COMMIT, similar rates of major bleeding were observed in the Plavix and placebo groups, both of which also received aspirin (see Table 2).
Table 2: Incidence of Bleeding Events in COMMIT (% patients) Type of Bleeding Plavix (+ aspirin) (n=22961) Placebo (+ aspirin) (n=22891) p-value Major Major bleeds were cerebral bleeds or noncerebral bleeds thought to have caused death or that required transfusion. noncerebral or cerebral bleeding 0.6 0.5 0.59 Major noncerebral 0.4 0.3 0.48 Fatal 0.2 0.2 0.90 Hemorrhagic stroke 0.2 0.2 0.91 Fatal 0.2 0.2 0.81 Other noncerebral bleeding (nonmajor) 3.6 3.1 0.005 Any noncerebral bleeding 3.9 3.4 0.004 CAPRIE (Plavix vs Aspirin) In CAPRIE, gastrointestinal hemorrhage occurred at a rate of 2.0% in those taking Plavix versus 2.7% in those taking aspirin; bleeding requiring hospitalization occurred in 0.7% and 1.1%, respectively. The incidence of intracranial hemorrhage was 0.4% for Plavix compared to 0.5% for aspirin.
Other bleeding events that were reported more frequently in the Plavix group were epistaxis and hematoma. Other Adverse Events In CURE and CHARISMA, which compared Plavix plus aspirin to aspirin alone, there was no difference in the rate of adverse events (other than bleeding) between Plavix and placebo. In CAPRIE, which compared Plavix to aspirin, pruritus was more frequently reported in those taking Plavix.
No other difference in the rate of adverse events (other than bleeding) was reported.
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of Plavix. Because these reactions are reported voluntarily from a population of an unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Hemorrhages, including those with fatal outcome, have been reported in patients treated with Plavix.
Blood and lymphatic system disorders: Agranulocytosis, aplastic anemia/pancytopenia, thrombotic thrombocytopenic purpura (TTP), acquired hemophilia A Gastrointestinal disorders: Colitis (including ulcerative or lymphocytic colitis), pancreatitis, stomatitis, gastric/duodenal ulcer, diarrhea General disorders and administration site condition: Fever Hepatobiliary disorders: Acute liver failure, hepatitis (noninfectious), abnormal liver function test Immune system disorders: Hypersensitivity reactions, anaphylactoid reactions, serum sickness, insulin autoimmune syndrome, which can lead to severe hypoglycemia Musculoskeletal, connective tissue and bone disorders: Myalgia, arthralgia, arthritis Nervous system disorders: Taste disorders, headache, ageusia Psychiatric disorders: Confusion, hallucinations Respiratory, thoracic and mediastinal disorders: Bronchospasm, interstitial pneumonitis, eosinophilic pneumonia Renal and urinary disorders: Increased creatinine levels Skin and subcutaneous tissue disorders: Maculopapular, erythematous or exfoliative rash, urticaria, bullous dermatitis, eczema, toxic epidermal necrolysis, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis (AGEP), angioedema, drug-induced hypersensitivity syndrome, drug rash with eosinophilia and systemic symptoms (DRESS), erythema multiforme, lichen planus, generalized pruritus Vascular disorders: Vasculitis, hypotension
Adverse reaction frequency tables (US label) US FDA label
| Event | Plavix (+ aspirin) (n=6259) | Placebo (+ aspirin) (n=6303) |
|---|---|---|
| Major bleedingLife-threatening and other major bleeding. | 3.7 | 2.7 |
| Life-threatening bleeding | 2.2 | 1.8 |
| Fatal | 0.2 | 0.2 |
| 5 g/dL hemoglobin drop | 0.9 | 0.9 |
| Requiring surgical intervention | 0.7 | 0.7 |
| Hemorrhagic strokes | 0.1 | 0.1 |
| Requiring inotropes | 0.5 | 0.5 |
| Requiring transfusion (≥4 units) | 1.2 | 1.0 |
| Other major bleeding | 1.6 | 1.0 |
| Significantly disabling | 0.4 | 0.3 |
| Intraocular bleeding with significant loss of vision | 0.05 | 0.03 |
| Requiring 2–3 units of blood | 1.3 | 0.9 |
| Minor bleedingLed to interruption of study medication. | 5.1 | 2.4 |
| Type of Bleeding | Plavix (+ aspirin) (n=22961) | Placebo (+ aspirin) (n=22891) | p-value |
|---|---|---|---|
| MajorMajor bleeds were cerebral bleeds or noncerebral bleeds thought to have caused death or that required transfusion. noncerebral or cerebral bleeding | 0.6 | 0.5 | 0.59 |
| Major noncerebral | 0.4 | 0.3 | 0.48 |
| Fatal | 0.2 | 0.2 | 0.90 |
| Hemorrhagic stroke | 0.2 | 0.2 | 0.91 |
| Fatal | 0.2 | 0.2 | 0.81 |
| Other noncerebral bleeding (nonmajor) | 3.6 | 3.1 | 0.005 |
| Any noncerebral bleeding | 3.9 | 3.4 | 0.004 |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Available data from cases reported in published literature and postmarketing surveillance with clopidogrel use in pregnant women have not identified any drug-associated risks for major birth defects or miscarriage [see Data]. There are risks to the pregnant woman and fetus associated with myocardial infarction and stroke [see Clinical Considerations].
No evidence of fetotoxicity was observed when clopidogrel was administered to pregnant rats and rabbits during organogenesis at doses corresponding to 65 and 78 times the recommended daily human dose [see Data]. The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown.
All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Myocardial infarction and stroke are medical emergencies.
Therapy for the pregnant woman should not be withheld because of potential concerns regarding the effects of clopidogrel on the fetus. Labor or delivery Clopidogrel use during labor or delivery will increase the risk of maternal bleeding and hemorrhage. Avoid neuraxial blockade during clopidogrel use because of the risk of spinal hematoma.
When possible, discontinue clopidogrel 5 to 7 days prior to labor, delivery, or neuraxial blockade. Data Human data The available data from published case reports over two decades of postmarketing use have not identified an association with clopidogrel use in pregnancy and major birth defects, miscarriage, or adverse fetal outcomes.
Animal data Embryo-fetal developmental toxicology studies were performed in pregnant rats and rabbits with doses up to 500 and 300 mg/kg/day, respectively, administered during organogenesis. These doses, corresponding to 65 and 78 times the recommended daily human dose, respectively, on a mg/m 2 basis, revealed no evidence of impaired fertility or fetotoxicity due to clopidogrel.
Mechanism of action
12.1 Mechanism of Action Clopidogrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y 12 class of ADP receptors on platelets.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation. The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y 12 receptor and the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.
This action is irreversible. Consequently, platelets exposed to clopidogrel's active metabolite are affected for the remainder of their lifespan (about 7 to 10 days). Platelet aggregation induced by agonists other than ADP is also inhibited by blocking the amplification of platelet activation by released ADP. Dose-dependent inhibition of platelet aggregation can be seen 2 hours after single oral doses of Plavix.
Repeated doses of 75 mg Plavix per day inhibit ADP-induced platelet aggregation on the first day, and inhibition reaches steady state between Day 3 and Day 7. At steady state, the average inhibition level observed with a dose of 75 mg Plavix per day was between 40% and 60%. Platelet aggregation and bleeding time gradually return to baseline values after treatment is discontinued, generally in about 5 days.
Geriatric Patients Elderly (≥75 years) and young healthy subjects had similar effects on platelet aggregation. Renally Impaired Patients After repeated doses of 75 mg Plavix per day, patients with severe renal impairment (creatinine clearance from 5 to 15 mL/min) and moderate renal impairment (creatinine clearance from 30 to 60 mL/min) showed low (25%) inhibition of ADP-induced platelet aggregation.
Hepatically Impaired Patients After repeated doses of 75 mg Plavix per day for 10 days in patients with severe hepatic impairment, inhibition of ADP-induced platelet aggregation was similar to that observed in healthy subjects. Gender In a small study comparing men and women, less inhibition of ADP-induced platelet aggregation was observed in women.
Pharmacokinetics
Absorption is at least 50%, based on urinary excretion of clopidogrel metabolites.
Elimination Following an oral dose of 14 C-labeled clopidogrel in humans, approximately 50% of total radioactivity was excreted in urine and approximately 46% in feces over the 5 days post dosing.
After a single, oral dose of 75 mg, clopidogrel has a half-life of approximately 6 hours.
The half-life of the active metabolite is about 30 minutes.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Clopidogrel is a prodrug and is metabolized to a pharmacologically active metabolite and inactive metabolites. Absorption After single and repeated oral doses of 75 mg per day, clopidogrel is rapidly absorbed. Absorption is at least 50%, based on urinary excretion of clopidogrel metabolites. Effect of food Plavix can be administered with or without food.
In a study in healthy male subjects when Plavix 75 mg per day was given with a standard breakfast, mean inhibition of ADP-induced platelet aggregation was reduced by less than 9%. The active metabolite AUC 0–24 was unchanged in the presence of food, while there was a 57% decrease in active metabolite C max. Similar results were observed when a Plavix 300 mg loading dose was administered with a high-fat breakfast.
Metabolism Clopidogrel is extensively metabolized by two main metabolic pathways: one mediated by esterases and leading to hydrolysis into an inactive carboxylic acid derivative (85% of circulating metabolites) and one mediated by multiple cytochrome P450 enzymes. Cytochromes first oxidize clopidogrel to a 2-oxo-clopidogrel intermediate metabolite.
Subsequent metabolism of the 2-oxo-clopidogrel intermediate metabolite results in formation of the active metabolite, a thiol derivative of clopidogrel. The active metabolite is formed mostly by CYP2C19 with contributions from several other CYP enzymes, including CYP1A2, CYP2B6 and CYP3A. The active thiol metabolite binds rapidly and irreversibly to platelet receptors, thus inhibiting platelet aggregation for the lifespan of the platelet.
The C max of the active metabolite is twice as high following a single 300 mg clopidogrel loading dose as it is after four days of 75 mg maintenance dose. C max occurs approximately 30 to 60 minutes after dosing. In the 75 to 300 mg dose range, the pharmacokinetics of the active metabolite deviates from dose proportionality: 4-fold the dose results in 2.0-fold and 2.7-fold the C max and AUC, respectively.
Elimination Following an oral dose of 14 C-labeled clopidogrel in humans, approximately 50% of total radioactivity was excreted in urine and approximately 46% in feces over the 5 days post dosing. After a single, oral dose of 75 mg, clopidogrel has a half-life of approximately 6 hours. The half-life of the active metabolite is about 30 minutes.
Drug Interactions Effect of other drugs on Plavix Clopidogrel is metabolized to its active metabolite in part by CYP2C19. CYP2C19 inducers Concomitant use of strong inducers of CYP2C19 results in increased plasma concentration of the active metabolite of clopidogrel and an increase in platelet inhibition. Rifampin: Coadministration of rifampin 300 mg twice daily for 7 days with 600 mg loading dose of clopidogrel in healthy adults increased the mean AUC and C max of clopidogrel's thiol metabolites by 3.8-fold.
Mean inhibition of platelet aggregation at 4 hours post dose was 34% higher in the presence of rifampin compared to clopidogrel administered alone. CYP2C19 inhibitors Concomitant use of certain inhibitors of this enzyme results in reduced plasma concentrations of the active metabolite of clopidogrel and a reduction in platelet inhibition.
Proton pump inhibitors (PPI) The effect of proton pump inhibitors (PPI) on the systemic exposure to the clopidogrel active metabolite following multiple doses of Plavix 75 mg evaluated in dedicated drug interaction studies is presented in Figure 1. Figure 1: Exposure to Clopidogrel Active Metabolite Following Multiple Doses of Plavix 75 mg Alone or with Proton Pump Inhibitors (PPIs) Pharmacodynamic and pharmacokinetic parameters measured in these studies showed that the interaction was highest with omeprazole and least with dexlansoprazole.
Figure Opioids Coadministration of 5 mg intravenous morphine with 600 mg loading dose of clopidogrel in healthy adults decreased the AUC and C max of clopidogrel's thiol metabolites by 34%. Mean platelet aggregation was higher up to 2 to 4 hours with morphine coadministration. Effect of Plavix on other drugs In vitro studies have shown that the glucuronide metabolite of clopidogrel is a strong inhibitor of CYP2C8.
Concomitant administration of repaglinide with Plavix increased the systemic exposure to repaglinide (AUC 0–∞) by 5.1-fold following the loading dose (300 mg) and by 3.9-fold on day 3 of the maintenance dose (75 mg) of Plavix [see Drug Interactions (7.6)].
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Clopidogrel 75 mg Tablet | ₱0.92–₱2.80Reference ₱1.11 | per tablet | DPRI procurement range |
| 75 mg tablet | ₱20.25 | per tablet | PhilHealth GAMOT fixed fee |
PhilHealth GAMOT fixed fee paid to the accredited GAMOT pharmacy per unit dispensed Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf, as of October 13, 2026
Formulary and coverage
| Philippine National Formulary | Listed as Clopidogrel |
| PNF listing | Oral: 75 mg tablet |
| PhilHealth GAMOT | Yes (listed since July 28, 2025) |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Plavix · Sanofi-Aventis U.S. LLC [US FDA-approved label, version 5, May 30, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de8b0b67-eb25-4684-83b5-7ad785314227
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .


